News
EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc (GC4K), an Australian non-profit foundation focused on research programs and clinical trials to find cures
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
Novocure (NASDAQ: NVCR) today announced a series of actions to strengthen and optimize business operations to support near-term growth drivers and long-term value creation. The plan includes an
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Charles River Laboratories to Present at Evercore ISI Investor Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29th, at 9:10 a.m. ET
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™
EQS-News: Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Sensorion Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the
EQS-News: MPH Health Care AG: Q3-Zahlen 2023 Eigenkapital (Net Asset Value) steigt gegenüber dem Vorjahreszeitraum um über 58 % auf 215,7 Mio. Euro per 30. September 2023.
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the
Savara to Present at the Piper Sandler 35th Annual Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023. William Doyle, Novocure’s Executive
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Abivax announces the resumption of its liquidity contract
Evolva enters into an agreement to sell its operations to Lallemand, securing the best possible outcome for the company and its stakeholders
EQS-News: Akribion Genomics receives the Hessian Founder Award for its innovative approach to a new cancer therapy
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, announced today that the European Commission (EC) has approved EBGLYSS (lebrikizumab) for the treatment